权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Benzodiazepine Choice and Polydrug Use

苯二氮卓类药物的选择和多种药物的使用

基本信息

批准号：
10444445
负责人：
Sally Huskinson
金额：
$ 55.58万
依托单位：
UNIVERSITY OF MISSISSIPPI MED CTR
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-04-01 至 2027-01-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10444445
关键词：
Address Adult Affect Alprazolam Animals Anxiety Disorders Attenuated Benzodiazepines Clinical Data Cocaine Dangerousness Data Development Drug Modelings Drug usage Exhibits Exposure to Food GABA Modulators General Population Goals Heroin Individual Knowledge Ligands Macaca mulatta Modeling Monkeys Opioid Overdose Pattern Pharmaceutical Preparations Pharmacology Procedures Psychological reinforcement Recording of previous events Reporting Research Risk Role Safety Self Administration Sleep Disorders Stimulant Substance Use Disorder Testing Therapeutic Toxic effect Training abuse liability addiction benzodiazepine abuse benzodiazepine misuse drug of abuse epidemiologic data experience experimental study improved multiple drug use non-drug novel strategies overdose death positive allosteric modulator preclinical evaluation predict clinical outcome programs receptor side effect therapeutic development

项目摘要

Project Summary Benzodiazepines (BZs) are effective and safe when used appropriately, but their utility is limited by unwanted side effects like misuse and reduced safety when combined with other drugs. Individuals with substance-use disorders (SUDs) misuse BZs as much as 20x greater than the general population, and the rising number of overdose deaths attributed to BZs are largely driven by opioid co-administration. Given the high rates of polydrug use among individuals who also misuse BZs, preclinical evaluations of BZs should consider the polydrug scenarios in which they are being misused. The goal of this research is to identify pharmacological determinants of BZ misuse, with the goal of identifying BZ-type ligands with reduced abuse potential in polydrug situations. We reported previously that nonselective, partial-efficacy BZ ligands or those that lack intrinsic efficacy at a1- subunit containing GABAA (a1GABAA) receptors have reduced abuse potential relative to traditional BZs. However, our data suggest that the degree to which these BZ-type ligands exhibit abuse potential depends on the subject’s drug history. This new application will use choice models to evaluate the overall hypothesis that drug experience is a key determinant of the role of GABAA receptor subtypes in the abuse potential of BZ-type ligands. A key finding from our choice research is that efficacy at a1GABAA receptors may be necessary for self- administration of BZs in cocaine-experienced subjects, but not required for enhancement of cocaine choice. It is unknown whether this pattern of effects is observed with other drugs of abuse, in particular opioids. Moreover, the pharmacological mechanism underlying these effects is unknown, with possibilities including (1) a differential role for a1GABAA receptors in reinforcement-enhancing vs. reinforcing effects of BZs alone, or (2) differences in overall intrinsic efficacy, irrespective of subtype selectivity. We will address these potential mechanisms in two Aims organized by unique approaches. In Aim 1, we will use drug vs. drug choice to evaluate the extent to which BZ-type ligands varying in efficacy and selectivity will enhance or attenuate drug choice when delivered as a combination with cocaine, heroin, or alprazolam in separate groups of subjects. In Aim 2, we will use drug vs. nondrug choice to evaluate the hypothesis that nonselective, partial modulators or a1-sparing BZs will have reduced reinforcing effects when delivered alone in subjects with a history of cocaine, heroin, alprazolam, or food choice. A significant addition to our groups of monkeys with different reinforcement histories will be the food-experienced animals, providing a quantitative model of drug-naïve individuals’ initial exposure to drug taking. BZ use among individuals with a SUD, in or out of treatment, is increasingly common and is associated with increased risk of BZ misuse and overdose. Testing the hypotheses proposed will provide critical information for understanding how past and current drug use affects the abuse liability of BZ-type drugs.

项目总结